Delivery of antisense oligonucleotides and plasmid DNA with various carrier agents

Antisense and Nucleic Acid Drug Development

Volumn 9, Issue 6, 1999, Pages 497-505

  Kang, Shin Hong ^a   Zirbes, Eric Lynn ^a   Kole, Ryszard ^a,b  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; DRUG CARRIER; EFFECTENE; EXGENE; LIPOFECTAMINE; LUCIFERASE; MESSENGER RNA; NUCLEIC ACID; ON 705; PLASMID DNA; UNCLASSIFIED DRUG;

ALTERNATIVE RNA SPLICING; ARTICLE; ASSAY; CONTROLLED STUDY; DRUG ACTIVITY; DRUG DELIVERY SYSTEM; HELA CELL; HUMAN; HUMAN CELL; PRIORITY JOURNAL;

BOVINAE;

EID: 0033403876     PISSN: 10872906     EISSN: None     Source Type: Journal    
DOI: 10.1089/oli.1.1999.9.497     Document Type: Article

References (13)

1. AGRAWAL, S., and IYER, R.P. (1997). Perspectives in antisense therapeutics. Pharmacol Ther. 76, 151-160.
2. BARRON, L.G., MEYER, K.B., and SZOKA, F.C. (1998). Effects of complement depletion on the pharmacokinetics and gene delivery mediated by cationic lipid-DNA complexes. Hum. Gene Ther. 9, 315-323.
3. BELTINGER, C., SARAGOVI, H.U., SMITH, R.M., LESAUTEUR, L., SHAH, N., DEDIONISIO, L., CHRISTENSEN, L., RAIBLE, A., JARETT, L., and GEWIRTZ, A.M. (1995). Binding, uptake, and intracellular trafficking of phosphorothioate-modified oligodeoxynucleotides. J. Clin. Invest. 95, 1814-1823.
4. BENNETT, C.F. (1998). Use of cationic lipid complexes for antisense oligonucleotide delivery. In: Applied Antisense Oligonucleotide Technology. C.A. Stein and A.M. Krieg, eds. (Wiley-Liss Inc, New York), pp. 129-145.
5. BENNETT, C.F., CHIANG, M.Y., CHAN, H., SHOEMAKER, J.E., and MIRABELLI, C.K. (1992). Cationic lipids enhance cellular up-take and activity of phosphorothioate antisense oligonucleotides. Mol. Pharmacol. 41, 1023-1033.
6. BERGAN, R., CONNELL, Y., FAHMY, B., and NECKERS, L. (1993). Electroporation enhances c-myc antisense oligodeoxynucleotide efficacy. Nucleic Acids Res. 21, 3567-3573.
7. BRASIER, A.R., TATE, J.E., and HABENER, J.F. (1989). Optimized use of the firefly luciferase assay as a reporter gene in mammalian cell lines. Biotechniques 7, 1116-1122.
8. CONDON, T.P., and BENNETT, C.F. (1996). Altered mRNA splicing and inhibition of human E-selectin expression by an antisense oligonucleotide in human umbilical cord vein endothelial cells. J. Biol. Chem. 271, 30398-30403.
9. CONRAD, A.H., BEHLKE, M.A., JAFFREDO, T., and CONRAD, G.W. (1998). Optimal lipofection reagent varies with the molecular modifications of the DNA. Antisense Nucleic Acid Drug Dev. 8, 427-434.
10. CROOKE, R.M. (1993). Cellular uptake, distribution and metabolism of phosphorothioate, phosphodiester, and methyl phosphonate oligonucleotides. In: Antisense Research and Applications. S.T. Crooke and B. Lebleu, eds. (CRC Press, Boca Raton, FL), pp. 427-449.
11. ZELPHATI, O., and SZOKA, F.C., Jr. (1996a). Intracellular distribution and mechanism of delivery of oligonucleotides mediated by cationic lipids. Pharmacol. Res. 13, 1367-1372.
12. ZELPHATI, O., and SZOKA, F.C., Jr. (1996b). Mechanism of oligonucleotide release from cationic liposomes. Proc. Natl. Acad. Sci. USA 93, 11493-11498.
13. ZELPHATI, O., UYECHI, L.S., BARRON, L.G., and SZOKA, F.C., Jr. (1998). Effect of serum components on the physico-chemical properties of cationic lipid/oligonucleotide complexes and on their interactions with cells. Biochem. Biophys. Acta 1390, 119-133.